The deal has been described as a “key element” of Clinical Data’s efforts to sell its non-core assets and focus its resources on its two late-stage targeted therapeutic programmes.
Susan Evans, vice president and general manager of Agencourt, said: "We are excited about the new opportunities and confident that these combined offerings will enable us to meet the full spectrum of service requirements -- sequencing, genotyping, gene expression, and DNA and RNA extraction -- for researchers around the world."